Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK)
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …

Accumulating clinical evidence indicates extensive inter-individual variations in the
effectiveness and adverse effects of standard treatment protocols, which are largely …

It is well‐accepted that off‐label drug dosing recommendations for pediatric patients should
be based on the best available evidence. However, the available traditional evidence is …

Significant interindividual and intraindividual variations on cytochrome P450 (CYP)-
mediated drug metabolism exist in the general population globally. Genetic polymorphisms …

The metabolism in eukaryotic cells is a highly ordered system involving various cellular
compartments, which fluctuates based on physiological rhythms. Organelles, as the smallest …

Genetic diseases disrupt the functionality of an infant's genome during fetal–neonatal
adaptation and represent a leading cause of neonatal and infant mortality in the United …

Purpose Personalized pharmacotherapy, including for the pediatric population, provides
optimal treatment and has emerged as a major trend owing to advanced drug therapeutics …

Introduction Pharmacokinetic parameters assessment is a critical aspect of drug discovery
and development, yet challenges persist due to limited training data. Despite advancements …

The anticonvulsant valproic acid (VPA) despite complex pharmacokinetics has been in
clinical use for nearly 6 decades. Previous reports indicated neonates, infants, and …

Pregnant women are frequently prescribed drugs to treat chronic diseases such as human
immunodeficiency virus infection, but little is known about the benefits and risks of these …